[
    [
        {
            "time": "2023-10-17",
            "original_text": "AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study",
            "features": {
                "keywords": [
                    "Imbruvica",
                    "pancreatic cancer",
                    "study failure"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "AbbVie's cancer drug fails to meet main goal in late-stage study",
            "features": {
                "keywords": [
                    "cancer drug",
                    "late-stage",
                    "study failure"
                ],
                "sentiment_score": -0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie's cancer drug fails to meet main goal in late-stage study",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer",
            "features": {
                "keywords": [
                    "Phase 3",
                    "Ibrutinib",
                    "metastatic pancreatic cancer"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts",
            "features": {
                "keywords": [
                    "biotech stocks",
                    "fourth-quarter",
                    "forecasts"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "earnings surprise",
                    "streak"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
            "features": {
                "keywords": [
                    "AbbVie",
                    "earnings growth",
                    "Wall Street"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Pacira's Study on Exparel Label Expansion Meets Endpoints",
            "features": {
                "keywords": [
                    "Pacira",
                    "Exparel",
                    "label expansion",
                    "meets endpoints"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pacira's Study on Exparel Label Expansion Meets Endpoints",
                "Correlation": 3,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Are you a Tortoise or a Hare Investor?",
            "features": {
                "keywords": [
                    "Tortoise",
                    "Hare",
                    "Investor"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Are you a Tortoise or a Hare Investor?",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 1,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon",
            "features": {
                "keywords": [
                    "Zacks Market Edge",
                    "Occidental",
                    "Gilead",
                    "AbbVie",
                    "AT&T",
                    "Verizon"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "healthcare",
                    "telecommunications"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]